Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 5/1997

01-07-1997 | ORIGINAL ARTICLE

Gene transfer of a hybrid interleukin-1β gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo

Authors: Olle Björkdahl, Anette Gjörloff Wingren, Gunnar Hedlund, Lennart Ohlsson, M. Dohlsten

Published in: Cancer Immunology, Immunotherapy | Issue 5/1997

Login to get access
Metadata
Title
Gene transfer of a hybrid interleukin-1β gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo
Authors
Olle Björkdahl
Anette Gjörloff Wingren
Gunnar Hedlund
Lennart Ohlsson
M. Dohlsten
Publication date
01-07-1997
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 5/1997
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050383

Other articles of this Issue 5/1997

Cancer Immunology, Immunotherapy 5/1997 Go to the issue

ORIGINAL ARTICLE

The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent

ORIGINAL ARTICLE

Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment

ORIGINAL ARTICLE

Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation

ORIGINAL ARTICLE

Interleukin-4 is effective in restoring cytotoxic T cell activity that declines during in vivo progression of a murine B lymphoma

ORIGINAL ARTICLE

Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients

ORIGINAL ARTICLE

Variant mouse lymphoma cells with modified response to interferon demonstrate enhanced immunogenicity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits